4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Tilapia develop protective immunity including a humoral response following exposure to tilapia lake virus.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tilapia lake virus (TiLV) is an emerging virus associated with high mortality in cultured tilapia. Since the first report of tilapia lake virus, it has been detected in diseased tilapia in sixteen countries around the world. Thus, there is an urgent need to develop an efficacious vaccine to prevent TiLV disease (TiLVD) and reduce its global economic impact. Understanding the role of the adaptive immune response following exposure of tilapia to TiLV is a critical step in the development of such a vaccine. In this study, we challenged red hybrid tilapia by cohabitation or intraperitoneal injection and demonstrated that surviving fish develop a protective immunity. We also demonstrated that tilapia that survived experimental infections possess significant antibodies against the protein encoded by the TiLV segment 4. We then developed a TiLV indirect ELISA to determine the antibody response in tilapia. The ELISA revealed high antibody levels in survivors of experimental challenges and following outbreaks on farms. The ELISA effectively distinguished TiLV-exposed from unexposed tilapia and was used to monitor anti-TiLV antibody kinetics following infection. During the primary infection, tilapia developed an antibody response as early as 7 days post TiLV challenge (dpc), peaked at 15 dpc, showed a gradual decline up until about 42 dpc, but persisted in some fish up until day 110 dpc. Upon re-infection, an increased antibody response occurred within 7-14 days, demonstrating that tilapia that survive TiLV infections develop humoral memory. In conclusion, our results demonstrated that tilapia mount antibody responses against TiLV that supports protective immunity to subsequent TiLV disease. The persistence of anti-TiLV antibodies in survivors following a single exposure suggests a single vaccination might be adequate to protect tilapia during the entire grow-out period. This study provides important information about the immune response of tilapia following exposure to TiLV as a first step in the development of an efficacious vaccine against this emerging and economically important viral disease.

          Related collections

          Author and article information

          Journal
          Fish Shellfish Immunol
          Fish & shellfish immunology
          Elsevier BV
          1095-9947
          1050-4648
          Nov 2020
          : 106
          Affiliations
          [1 ] Department of Veterinary Microbiology and Immunology, Faculty of Veterinary Medicine, Kasetsart University. Thailand; Center for Advanced Studies for Agriculture and Food, Kasetsart University, Institute for Advanced Studies, Kasetsart University, Bangkok, 10900, Thailand (CASAF, NRU-KU), Thailand.
          [2 ] Department of Infectious Diseases and Immunology, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA; Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA.
          [3 ] Department of Veterinary Microbiology and Immunology, Faculty of Veterinary Medicine, Kasetsart University. Thailand; Center for Advanced Studies for Agriculture and Food, Kasetsart University, Institute for Advanced Studies, Kasetsart University, Bangkok, 10900, Thailand (CASAF, NRU-KU), Thailand. Electronic address: fvetwsp@ku.ac.th.
          Article
          S1050-4648(20)30594-5
          10.1016/j.fsi.2020.08.031
          32858185
          038aa3aa-ec89-4763-9279-a82edb9f4eb7
          History

          Immunity,ELISA,Tilapia,Tilapia lake virus,Antibody,TiLV
          Immunity, ELISA, Tilapia, Tilapia lake virus, Antibody, TiLV

          Comments

          Comment on this article